zurück

Birch bark extract (wounds associated with dystrophic and junctional epidermolysis bullosa (EB), patients aged ≥ 6 months)

 

Subject:

  • Active Sustance: Birch bark
  • Name: Filsuvez®
  • Therapeutic area: Dystrophic and junctional epidermolysis bullosa (EB)
  • Pharmaceutical company: Amryt Pharma GmbH

 

Time table:

  • Start: 01.09.2022
  • Final decision by G-BA: 16.02.2023

 

Final decision:

  • Hint for a minor additional benefit